Total Valuation
XBiotech has a market cap or net worth of CHF55.16M. The enterprise value is -CHF43.20M.
Market CapCHF55.16M
Enterprise Value-CHF43.20M
Share Statistics
XBiotech has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders―
Owned by Institutions0.04%
Financial Efficiency
XBiotech’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -39.17%.
Return on Equity (ROE)-0.32
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-39.17%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee0.00
Profits Per Employee-495.00K
Employee Count92
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of XBiotech is ―. XBiotech’s PEG ratio is -0.09.
PE Ratio―
PS Ratio0.00
PB Ratio0.52
Price to Fair Value0.52
Price to FCF-1.81
Price to Operating Cash Flow-1.61
PEG Ratio-0.09
Income Statement
In the last 12 months, XBiotech had revenue of 0.00 and earned -45.54M in profits. Earnings per share was -1.49.
Revenue0.00
Gross Profit-1.69M
Operating Income-55.69M
Pretax Income-45.30M
Net Income-45.54M
EBITDA-43.53M
Earnings Per Share (EPS)-1.49
Cash Flow
In the last 12 months, operating cash flow was -42.17M and capital expenditures -195.00K, giving a free cash flow of -42.36M billion.
Operating Cash Flow-42.17M
Free Cash Flow-42.36M
Free Cash Flow per Share-10.00T>
Dividends & Yields
XBiotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.26
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
XBiotech upcoming earnings date is May 9, 2019, TBA (Confirmed).
Last Earnings DateMar 14, 2019
Next Earnings DateMay 9, 2019
Ex-Dividend Date―
Financial Position
XBiotech as a current ratio of 16.01, with Debt / Equity ratio of 0.00%
Current Ratio16.01
Quick Ratio16.01
Debt to Market Cap0.00
Net Debt to EBITDA2.88
Interest Coverage Ratio-632.78
Taxes
In the past 12 months, XBiotech has paid 235.00K in taxes.
Income Tax235.00K
Effective Tax Rate>-0.01
Enterprise Valuation
XBiotech EV to EBITDA ratio is 1.21, with an EV/FCF ratio of 1.31.
EV to Sales0.00
EV to EBITDA1.21
EV to Free Cash Flow1.31
EV to Operating Cash Flow1.32
Balance Sheet
XBiotech has CHF115.46M in cash and marketable securities with CHF0.00 in debt, giving a net cash position of CHF115.46M billion.
Cash & Marketable SecuritiesCHF115.46M
Total DebtCHF0.00
Net CashCHF115.46M
Net Cash Per ShareCHF10.00T>
Tangible Book Value Per ShareCHF4.60
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for XBiotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―